Seres Therapeutics, Inc. (MCRB) Total liabilities 2016–2025
Seres Therapeutics, Inc. (MCRB) total liabilities at each fiscal year-end, per SEC filings.
$94.0MFY2025 · since FY2016: $140.0M → $94.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $94.0M | -25.4% |
| FY2024 | $126.0M | -68.8% |
| FY2023 | $403.5M | +19.4% |
| FY2022 | $338.0M | +51.3% |
| FY2021 | $223.4M | +32.8% |
| FY2020 | $168.2M | -7.0% |
| FY2019 | $180.8M | +7.3% |
| FY2018 | $168.5M | +30.8% |
| FY2017 | $128.8M | -8.0% |
| FY2016 | $140.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More MCRB financial trends
MCRB RevenueMCRB Net incomeMCRB Net marginMCRB Gross profitMCRB Gross marginMCRB Operating incomeMCRB Operating marginMCRB Operating cash flowMCRB Free cash flowMCRB Capital expendituresMCRB Return on equityMCRB Stock buybacksMCRB Dividends paidMCRB Total assetsMCRB Shareholders’ equityMCRB overview →